Shares in Iveric Bio are continuing to soar after the small US biotech said its lead asset Zimura slowed eyesight deterioration in patients with dry age-related macular degeneration (AMD).
Iveric's Zimura Succeeds In Dry AMD Study
Stock Sees Three-Day Gain Of 283%
The New York-headquartered firm, which recently decided to focus on gene therapy, has to decide whether to partner Zimura or go it alone.
More from Sensory
• By
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
• By
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
• By
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
• By
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.
More from Therapy Areas
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.